Study guide
Adolescent Confidentiality, Risk Behaviours, Reproductive Health, and Eating Disorders
EBP-EAP Examination in Paediatrics Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Structure, Governance, Ethics & Child Safeguarding
EBP-EAP Format, Delivery, Scoring, and Clinical Vignette Strategy Paediatric Ethics, Consent/Assent, Gillick Competence, and Patient Safety Child Protection, Physical/Emotional Abuse, Neglect, and Non-Accidental Injury (NAI)
2 Chapter 2: Neonatal Transition, Resuscitation & Prematurity
Delivery Room Care, Apgar Scoring, and Neonatal Resuscitation Algorithm Respiratory Distress Syndrome (RDS), Surfactant Therapy, and Bronchopulmonary Dysplasia Perinatal Asphyxia, HIE Sarnat Staging, and Therapeutic Hypothermia Protocol
3 Chapter 3: Neonatal Morbidities, Jaundice & Congenital Infections
Unconjugated vs Conjugated Hyperbilirubinemia, Phototherapy Thresholds, and Exchange Transfusion Early- vs Late-Onset Sepsis, Group B Streptococcus, and Congenital TORCH Infections NEC Diagnosis/Bell Staging, Neonatal Hypoglycaemia, and Newborn Bloodspot Screening
4 Chapter 4: Acute Paediatric Emergencies & Critical Care
EPLS/PALS Structured Approach, Types of Shock, and Weight-Based Fluid Boluses Clinical Diagnostic Criteria, Intramuscular Adrenaline Dosing, and Refractory Anaphylaxis 5-Minute Time-Critical Anticonvulsant Protocol and Status Epilepticus Care Common Toxidromes (Paracetamol, Iron, Caustics, Button Batteries) and Decontamination
5 Chapter 5: Paediatric Respiratory Medicine
Stridor Differential, Croup (Westley Score & Dexamethasone), and Epiglottitis RSV Pathogenesis, Supportive Management, Oxygen/High-Flow Criteria, and Futility of Bronchodilators/Steroids European/BTS Guidelines on Chronic Stepwise Control and Acute Severe Exacerbation Management Community-Acquired Pneumonia Etiology, Parapneumonic Effusion/Empyema, and Cystic Fibrosis Pulmonary Exacerbations
6 Chapter 6: Paediatric Cardiology
Acyanotic vs Cyanotic Congenital Heart Disease: Ductal Patency, Shunt Lesions, and Emergency Stabilization Paediatric Murmurs and Arrhythmias: Innocent vs Pathological Murmurs, SVT, and Resuscitation Protocols Acquired Heart Disease: Kawasaki Disease, Coronary Aneurysm Prevention, and Acute Rheumatic Fever
7 Chapter 7: Paediatric Gastroenterology, Hepatology & Nutrition
Dehydration Severity Assessment, Oral Rehydration Therapy (ORT), and Intravenous Fluid Protocols ESPGHAN Coeliac Diagnostic Criteria (Biopsy-Sparing Pathway) and Paediatric Crohn's/Ulcerative Colitis Breastfeeding, Formula Selection, Cow's Milk Protein Allergy (CMPA), GERD vs GOR, and Faltering Growth Prolonged Neonatal Jaundice Workup, Biliary Atresia Red Flags, and Acute Hepatitis/Liver Failure
8 Chapter 8: Paediatric Nephrology, Fluids & Electrolyte Balance
Paediatric UTI Diagnosis, Imaging Criteria (Ultrasound/DMSA/MCUG), and Vesicoureteral Reflux Minimal Change Nephrotic Syndrome (Steroid Regimen & Complications) vs Acute Post-Infectious Glomerulonephritis Paediatric AKI (pRIFLE/KDIGO), Haemolytic Uraemic Syndrome (HUS), and Hyperkalaemia/Dysnatraemia Management
9 Chapter 9: Paediatric Endocrinology & Inborn Errors of Metabolism
Paediatric DKA Protocol (ISPAD/European Fluid & Insulin Guidelines, Cerebral Oedema Prevention) and T1DM Maintenance Congenital Hypothyroidism Screening & Levothyroxine, Congenital Adrenal Hyperplasia (21-Hydroxylase Deficiency), and Adrenal Crisis Short Stature Workup, Precocious vs Delayed Puberty, and Approach to Suspected Inborn Errors of Metabolism (IEM)
10 Chapter 10: Paediatric Neurology, Neurodevelopment & Mental Health
Simple vs Complex Febrile Seizures, Childhood Epilepsy Syndromes (Absence, Infantile Spasms, Benign Rolandic), and Antiseizure Medications Red Flags for Raised Intracranial Pressure (ICP), Brain Tumours, Migraine vs Tension Headache Acute Bacterial Meningitis (LP Contraindications, Ceftriaxone, Dexamethasone) and Viral Encephalitis (Aciclovir) Developmental Milestones (Gross Motor, Fine Motor/Vision, Speech/Language, Social), Autism Spectrum, ADHD, and Cerebral Palsy
11 Chapter 11: Paediatric Haematology & Oncology
Microcytic Anaemia (Iron Deficiency vs Thalassaemia Trait/Mentzer Index), Haemolytic Anaemias (Spherocytosis, G6PD) Sickle Cell Crises (Vaso-occlusive, Acute Chest Syndrome, Stroke Prevention), Immune Thrombocytopenia (ITP), and Haemophilia A/B Acute Lymphoblastic Leukaemia (ALL), Neuroblastoma, Wilms Tumour, and Management of Febrile Neutropenia
12 Chapter 12: Paediatric Infectious Diseases, Immunology & Allergy
Common Childhood Exanthems: Clinical Morphology, Timelines, Complications, and Management Paediatric Tuberculosis, Sepsis Six in Children, and Acute Osteoarticular Infections Pediatric Allergy, Atopic Eczema, Food Hypersensitivity, and Desensitization Primary Immunodeficiencies, Warning Signs, Live Vaccine Contraindications, and European Immunisation Schedules
13 Chapter 13: Paediatric Musculoskeletal, Dermatology & Surgical Conditions
The Limping Child, Septic Arthritis vs Transient Synovitis, and Juvenile Idiopathic Arthritis Henoch-Schönlein Purpura, Kawasaki Disease vs MIS-C, Infantile Haemangiomas, and Common Pediatric Eruptions Acute Appendicitis, Intussusception, Pyloric Stenosis, Testicular Torsion, and Incarcerated Hernia
14 Chapter 14: Research Methods, Biostatistics & Evidence-Based Paediatrics
Study Designs, Causality, Bias, and Epidemiological Measures in Paediatrics Diagnostic Test Accuracy, Statistical Inference, and Hypothesis Testing Systematic Reviews, Meta-Analysis, Decision Analysis, and Paediatric Research Ethics
15 Chapter 15: Paediatric Ophthalmology & ENT Disorders
Paediatric Vision Assessment, Refractive Disorders, Strabismus, and Leukocoria Ocular Emergencies, Orbital Infections, ROP, and Systemic Manifestations Paediatric Otolaryngology: Otitis Media, Hearing Impairment, and Upper Airway Conditions
16 Chapter 16: Paediatric Sports Medicine & Musculoskeletal Health
Skeletal Maturity, Physeal Injuries, Apophysitis, and Overuse Syndromes Paediatric Sports Concussion, Second Impact Syndrome, and Return-to-Play Protocols Pre-Participation Screening, Physical Activity Guidelines, and Chronic Disease Clearance
17 Chapter 17: Adolescent Medicine & Healthcare Transition
Biopsychosocial Development, Pubertal Staging, and Adolescent Communication Adolescent Confidentiality, Risk Behaviours, Reproductive Health, and Eating Disorders Chronic Illness in Adolescence and Structured Healthcare Transition
18 Chapter 18: Paediatric Genetics, Dysmorphology & Clinical Genomics
Patterns of Inheritance, Non-Mendelian Mechanisms, and Pedigree Construction Clinical Dysmorphology, Chromosomal Aneuploidies, and Microdeletion Syndromes Genetic Testing Technologies, Prenatal Diagnosis, and Genetic Counselling Ethics
19 Chapter 19: Paediatric Mental Health, Behaviour & Community Medicine
Cognitive Development, Attachment, Screening, and Common Emotional Disorders Regulatory Disorders, Neurodevelopmental Behavioural Conditions, and Psychosomatic Illness Community Child Healthcare Structures, Disability Coordination, and Child Advocacy
Adolescent Confidentiality, Risk Behaviours, Reproductive Health, and Eating Disorders
Key Takeaways Explain This Topic AI
Adolescent consent depends on the applicable national law and the decision being made. UK Gillick competence and Fraser guidance illustrate capacity-based consent and confidential contraceptive care; they are not a single European legal rule.
Protect adolescent confidentiality and explain its limits before sensitive discussion. Apply national law and safeguarding duties; necessary disclosure should be proportionate, limited to relevant information and normally discussed with the young person unless doing so increases risk.
Substance misuse screening with the validated CRAFFT tool (score ≥ 2 \ge 2 ≥ 2 indicates significant risk) should trigger non-confrontational brief motivational interviewing exploring ambivalence and fostering harm reduction.
Long-Acting Reversible Contraceptives (LARCs), including the etonogestrel subdermal implant and levonorgestrel intrauterine device (LNG-IUD), represent first-line contraception for adolescents due to top-tier, user-independent efficacy; emergency contraception options comprise oral levonorgestrel (UK licence: 72 hours; selected later use is off-label), oral ulipristal acetate (within 120 hours), or the copper IUD.
Eating disorders need urgent medical assessment for bradycardia, hypotension, postural instability, hypothermia, ECG or electrolyte abnormalities and rapid weight loss, including at normal BMI. Use an age-appropriate admission framework and a specialist refeeding plan with thiamine, monitoring and electrolyte replacement matched to risk.
Last updated: November 2026
Adolescent Confidentiality, Risk Behaviours, Reproductive Health, and Eating Disorders
Adolescent healthcare demands a sophisticated understanding of evolving legal competence, confidential risk mitigation, reproductive rights, and life-threatening behavioural emergencies. Paediatricians frequently navigate complex ethical dilemmas where parental desires conflict with adolescent autonomy, necessitating an objective, evidence-based approach grounded in European clinical standards.
Legal and Ethical Frameworks in European Adolescent Healthcare
The legal landscape governing adolescent healthcare balances parental rights with the young person's evolving developmental capacity. While paediatric care historically relied on parental consent, modern medical ethics recognizes that capacity is decision-specific rather than strictly determined by chronological age.
Consent versus Assent
Paediatric Assent : The affirmative agreement of a child or young person who lacks full legal competence to participate in healthcare interventions. Obtaining assent respects developing autonomy by providing age-appropriate information, answering questions, and soliciting the patient's agreement, even when parental permission is legally definitive.
Independent Legal Consent : The autonomous, legally binding authorization for medical treatment provided by a young person who possesses sufficient cognitive capacity and emotional maturity to fully appreciate the proposed intervention.
Evolving Capacity: Fraser Guidelines and Gillick Competence
In England and Wales, the 1985 Gillick judgment permits an under-16 with sufficient maturity and understanding to consent to the particular treatment. Other European jurisdictions use their own legal rules; assess the young person’s understanding and apply the law governing the consultation.
For confidential contraceptive advice and treatment for an under-16 in the UK, the Fraser guidelines require the following five criteria. They are not a general consent test for every sensitive treatment: +--------------------------------------------------------------------------+
- | THE FIVE FRASER GUIDELINES CRITERIA |
- | |
- | 1. The young person possesses sufficient maturity to understand the |
- | nature, purpose, risks, and implications of the proposed treatment. |
- | 2. The clinician cannot persuade the young person to inform their |
- | parents, nor will the adolescent permit the clinician to do so. |
- | 3. The young person is very likely to begin or continue sexual activity |
- | with or without contraceptive treatment. |
- | 4. The physical or mental health (or both) of the young person is |
- | likely to suffer unless they receive contraceptive advice or care. |
- | 5. The best interests of the young person require the provision of |
- | treatment/advice without parental involvement. |
- +--------------------------------------------------------------------------+
European countries differ in their legal ages, capacity tests and requirements for parental authorisation or joint consent. Do not infer a uniform right to independent medical consent from a country’s age threshold alone. Apply the national rules for the particular intervention while involving the adolescent in the decision.
Confidentiality and Lawful Disclosure
Confidentiality is an indispensable prerequisite for adolescent healthcare. Empirical data demonstrates that when adolescents fear parental disclosure, up to 50% avoid seeking care for sexually transmitted infections, contraception, mental health crises, or substance use.
Applying the Limits of Confidentiality
Confidentiality is the starting point, but its exceptions depend on national law and the clinical circumstances. UK GMC guidance permits disclosure without consent when required by law or a court, justified by overriding public interest, or necessary in the best interests of a young person who cannot decide about disclosure.
Serious-harm concerns include suicidal behaviour, dangerous substance use or driving, threats to others, and abuse, neglect or exploitation. They need a documented, proportionate assessment; risk need not fit a fixed three-event list. Seek safeguarding or senior advice when uncertain.
Share only relevant information with appropriate people. Normally tell the adolescent what will be disclosed and why, and involve them in the discussion. Do not give advance warning when it would increase danger, undermine safeguarding or otherwise defeat the disclosure's purpose. Parental disclosure is not automatic whenever a health risk is identified.
Adolescent Risk-Taking and Substance Misuse
Adolescent substance experimentation reflects the interplay between biological reward-seeking and social environments. ESPAD 2024 surveys of European students aged 15–16 show long-term declines in cigarette smoking, alcohol use, binge drinking and cannabis use, alongside increasing e-cigarette use and non-medical pharmaceutical use.
The CRAFFT Screening Questionnaire (Version 2.1)
The CRAFFT questionnaire is the most widely validated behavioural health screening tool for children and adolescents aged 12 to 21 years. First ask the Part A past-year frequency questions. If all answers are zero, ask CAR only; if any use is reported, ask all six CRAFFT items. Each positive item scores one point:
Item Mnemonic Clinical Question Diagnostic Significance
C — Car “Have you ever ridden in a CAR driven by someone (including yourself) who was 'high' or had been using alcohol or drugs?” Assesses acute, high-lethality environmental safety risk.
R — Relax “Do you ever use alcohol or drugs to RELAX, feel better about yourself, or fit in?” Identifies psychological self-medication for anxiety, depression, or social stress.
A — Alone “Do you ever use alcohol or drugs while you are by yourself, ALONE?” Identifies solitary use and prompts assessment of coping, harms and dependence; it does not diagnose addiction.
F — Forget “Do you ever FORGET things you did while using alcohol or drugs?” Indicates neurochemical intoxication, anterograde amnesia, and blackouts.
F — Friends “Do your family or FRIENDS ever tell you that you should cut down on your drinking or drug use?” Highlights interpersonal strain, objective functional impairment, and external concern.
T — Trouble “Have you ever gotten into TROUBLE while you were using alcohol or drugs?” Assesses adverse legal, scholastic, or behavioural consequences. +--------------------------------------------------------------------------+
- | CRAFFT SCORING & CLINICAL ACTION |
- | |
- | No past-year use AND score 0: LOW RISK |
- | --> Reinforce healthy choices; discuss substance/driving safety. |
- | |
- | No use but CAR positive, OR any use with score 0–1: MEDIUM RISK |
- | --> Brief advice, safety planning and follow-up as appropriate. |
- | |
- | Past-year use AND score >=2: HIGH RISK |
- | --> Brief intervention, further assessment and follow-up; |
- | consider referral according to severity and treatment needs. |
- +--------------------------------------------------------------------------+
- Brief Motivational Interviewing (MI)
Confrontational, punitive lecturing provokes defensiveness and paradoxically reinforces substance use. Clinicians must utilize Motivational Interviewing (MI) techniques grounded in the OARS framework :
O — Open-Ended Questions : “What are some of the things you enjoy about vaping with friends, and what are some things you dislike?”
A — Affirmations : “I really appreciate your honesty in sharing this with me today—it takes courage to talk openly about alcohol use.”
R — Reflective Listening : “So, smoking cannabis helps you unwind when school feels overwhelming, but you're finding it harder to wake up for morning classes.”
S — Summarizing : Integrating the adolescent's stated personal values with their substance use to elicit internal dissonance and stimulate 'change talk' .
Adolescent Sexual and Reproductive Healthcare
Adolescent reproductive healthcare must be accessible, confidential, and technically rigorous. Clinicians must provide comprehensive sexuality education, promote dual-protection strategies, conduct proactive STI screening, and recommend high-efficacy contraception.
Sexually Transmitted Infection (STI) Surveillance
Young people carry a substantial STI burden in Europe; reported chlamydia rates are highest in young adults, while gonorrhoea age patterns vary by sex and exposure group. Anatomical vulnerabilities, such as cervical ectopy (presence of delicate, single-cell columnar epithelium on the ectocervix), increase biological susceptibility to pathogens.
Chlamydia trachomatis and Neisseria gonorrhoeae : Chlamydia is often asymptomatic. Gonorrhoea is usually symptomatic in the male urethra but often silent at cervical, rectal or pharyngeal sites. First-catch morning urine nucleic acid amplification testing (NAAT) in males or self-collected vulvovaginal swabs in females offer non-invasive, highly sensitive screening.
Human Papillomavirus (HPV) : Vaccinate before HPV exposure using the current national programme . The 9-valent vaccine covers types 6, 11, 16, 18, 31, 33, 45, 52 and 58, preventing associated cancers and anogenital warts. Routine schedules may use one or two doses; for example, England uses one dose at 12–13 years, with three doses for immunosuppressed or HIV-positive recipients.
Dual Protection : Clinicians must emphasize that while hormonal and intrauterine contraceptives prevent pregnancy, they provide zero protection against STIs. Barrier condoms must be utilized concurrently for all penetrative sexual encounters.
Adolescent Contraception Hierarchy
Modern guidelines from the World Health Organization (WHO), European Society of Contraception (ESC), and American Academy of Pediatrics (AAP) designate Long-Acting Reversible Contraception (LARC) as the first-line choice for adolescents due to near-zero failure rates that are completely independent of daily adherence.
Contraceptive Modality Mechanism of Action Efficacy (Typical vs Perfect Failure Rate) Duration of Use Adolescent Advantages & Clinical Pearls
Etonogestrel Subdermal Implant (Nexplanon) Progestin release inhibits ovulation; thickens cervical mucus; atrophies endometrium. <0.05% (Top-tier efficacy; user-independent). 3 to 5 years First-line choice . Single 4 cm rod inserted subdermally into upper non-dominant arm. Does not require pelvic exam. Main side effect is unpredictable irregular bleeding; pre-insertion counseling prevents premature removal.
Levonorgestrel Intrauterine Device (LNG-IUD) Local progestin release thickens cervical mucus; suppresses endometrial proliferation; inhibits sperm motility. <0.2% (Top-tier efficacy; user-independent). 3 to 8 years (depending on model: 52 mg, 19.5 mg, 13.5 mg) First-line choice . Debunks outdated myths: LNG-IUD is completely safe, highly tolerable, and effective in nulliparous adolescents. Markedly reduces dysmenorrhea and menorrhagia.
Copper Intrauterine Device (Cu-IUD) Sterile foreign-body inflammatory reaction toxic to sperm and ova; prevents fertilization. <0.8% 5 to 10 years 100% hormone-free; maintains regular ovulatory cycles. Highly effective as post-coital emergency contraception. May increase menstrual cramps and bleeding volume.
Combined Oral Contraceptive Pill (COCP) Estrogen + progestin suppress pituitary FSH/LH secretion, inhibiting ovulation; thickens cervical mucus. 7%–9% typical failure (due to missed pills); <0.3% perfect. Daily administration Non-contraceptive benefits: treats acne vulgaris, dysmenorrhea, menorrhagia, and endometriosis. Contraindications: migraine with visual aura, uncontrolled hypertension, history of venous thromboembolism, prolonged immobilization.
Depot Medroxyprogesterone Acetate (DMPA) High-dose progestin injection suppresses GnRH and blocks LH surge. 4%–6% typical failure ; <0.2% perfect. Intramuscular injection every 12 weeks User-controlled, private. High risk of amenorrhea. Drawbacks: potential weight gain, delayed return of fertility ( 6 – 12 months 6\text{--}12\text{ months} 6 – 12 months ), reversible decrease in bone mineral density (calcium/vitamin D optimization essential).
Emergency Contraception (EC)
Emergency contraception must be provided rapidly without barriers following unprotected sexual intercourse, condom breakage, or sexual assault. +--------------------------------------------------------------------------+
- | EMERGENCY CONTRACEPTION TIMELINE & EFFICACY |
- | |
- | [ 0 to 72 Hours Post-Coitus ] |
- | --> Oral Levonorgestrel 1.5 mg single dose |
- | - Delays LH surge; efficacy decreases over time |
- | - Reduced efficacy in patients weighing >70 kg (BMI >25 kg/m2) |
- | |
- | [ 0 to 120 Hours (5 Days) Post-Coitus ] |
- | --> Oral Ulipristal Acetate (UPA) 30 mg single dose |
- | - Selective Progesterone Receptor Modulator |
- | - Delays follicular rupture even after LH has begun to rise |
- | - SUPERIOR efficacy to levonorgestrel; consistent across 120 hrs |
- | |
- | --> Copper Intrauterine Device (Cu-IUD) |
- | - Inserted up to 5 days (120 hrs) post-coitus |
- | - MOST EFFECTIVE EC (>99.9% effective); immediate long-term method |
- +--------------------------------------------------------------------------+
Tip
When evaluating an adolescent between 72 and 120 hours (Day 4–5) post-unprotected intercourse requesting oral emergency contraception, Ulipristal Acetate 30 mg is the oral agent of choice. Levonorgestrel is licensed to 72 hours in UK guidance, but may be considered off-label to 96 hours; it is less effective than UPA in this later window. Oral EC works before ovulation and should be taken promptly.
Adolescent Eating Disorders: Clinical Phenotypes and Red Flags
Eating disorders are life-threatening psychiatric conditions with profound somatic consequences, demonstrating peak onset during early-to-middle adolescence.
Diagnostic Spectra (DSM-5 & ICD-11)
Anorexia Nervosa (AN) : Persistent restriction of energy intake leading to significantly low body weight; intense fear of gaining weight or becoming fat; distorted perception of body weight/shape. Categorized into:
Restricting Type : Weight loss accomplished primarily through dieting, fasting, and excessive exercise without binge/purging.
Binge-Eating / Purging Type : Recurrent binge eating or purging (self-induced vomiting or misuse of laxatives, diuretics or enemas); both need not occur together.
Bulimia Nervosa (BN) : Recurrent episodes of binge eating accompanied by a sense of lack of control, followed by inappropriate compensatory behaviors (purging, fasting, over-exercising) to prevent weight gain. Weight is often within the normal range; interpret adolescent BMI for age and sex rather than using adult cutoffs. Somatic markers include bilateral parotid sialadenosis, dental perimylolysis (enamel erosion from gastric acid), Russell sign (calluses on dorsal metacarpophalangeal joints from induced gagging), and hypokalaemic hypochloraemic metabolic alkalosis.
Avoidant/Restrictive Food Intake Disorder (ARFID) : Clinically significant failure to meet nutritional needs leading to weight loss, nutritional deficiency, or oral supplement dependency. Crucially, ARFID lacks body image distortion or fear of fatness ; intake restriction is driven by sensory sensitivity (texture, smell), lack of interest in eating, or fear of aversive consequences (phobia of choking, dysphagia, or vomiting).
Clinical Examination Red Flags and Medical Admission Criteria
Paediatricians must not rely on subjective patient reporting; eating disorders carry high biological denial. Admission considers physiological instability, nutritional trajectory, mental health, outpatient resources and family support. SAHM 2022 lists the following factors supporting hospitalisation; NICE/MEED require comprehensive, age-appropriate assessment rather than one universal cutoff or BMI alone.
Parameter Factors Supporting Hospitalisation (SAHM 2022) Clinical Assessment
Heart rate <50 bpm daytime or <45 bpm at night Assess symptoms, perfusion and rhythm; profound bradycardia needs urgent care.
Blood pressure <90/45 mmHg Interpret with age, hydration, symptoms and trends.
Orthostatic change Sustained HR rise >40 bpm in adolescents <19 , or BP fall >20 systolic or >10 diastolic mmHg Assess syncope and circulatory instability; adult pulse thresholds differ.
Temperature <35.6°C Hypothermia indicates physiological compromise.
ECG Prolonged QTc or severe bradycardia Evaluate electrolytes and medications; significant abnormalities may require telemetry.
Hydration/electrolytes Dehydration, hypokalaemia, hyponatraemia or hypophosphataemia Judge severity and replacement needs; severe derangements require urgent monitored treatment.
Nutrition/clinical course ≤75% median BMI , arrested growth, acute food refusal, uncontrolled purging or failed outpatient care Rapid weight loss and acute complications can require admission at any BMI.
Refeeding Syndrome: Pathophysiology and Prevention
Refeeding syndrome is a potentially fatal metabolic complication occurring when carbohydrate nutrition is rapidly reintroduced into a chronically malnourished, starved patient. +--------------------------------------------------------------------------+
- | PATHOPHYSIOLOGY OF REFEEDING SYNDROME |
- | |
- | Chronic Starvation / Severe Caloric Restriction |
- | - Catabolism: Lipolysis and protein breakdown provide substrate |
- | - Whole-body depletion of Phosphate, Potassium, Magnesium |
- | - Basal insulin levels severely suppressed; glucagon elevated |
- | │ |
- | ▼ |
- | Rapid Re-introduction of Carbohydrates / High-Calorie Feeding |
- | │ |
- | ▼ |
- | Surge in Pancreatic Insulin Secretion |
- | │ |
- | ▼ |
- | Massive Cellular Uptake of Glucose, Phosphate (PO4), K+, Mg2+ |
- | - Phosphate consumed to synthesize ATP and 2,3-BPG |
- | │ |
- | ▼ |
- | FULMINANT BIOCHEMICAL DEFICITS IN EXTRACELLULAR COMPARTMENT: |
- | 1. Hypophosphataemia: Loss of ATP --> Diaphragmatic weakness, |
- | impaired myocardial contractility, acute rhabdomyolysis, seizures |
- | 2. Hypokalaemia: Cardiac arrhythmias, cardiac arrest, paralytic ileus |
- | 3. Hypomagnesaemia: Refractory hypokalaemia, tetany, torsades |
- | 4. Fluid Retention: Sodium and water retention --> Acute pulmonary |
- | edema and congestive heart failure |
- +--------------------------------------------------------------------------+
- Evidence-Based Prevention and Management
Pre-Feeding Baseline Assessment : Measure baseline serum phosphate, potassium, magnesium, calcium, renal function, liver enzymes, and an 12-lead ECG prior to starting nutritional rehabilitation.
Thiamine Supplementation : Starvation depletes thiamine (vitamin B 1 B_1 B 1 ) , a critical cofactor in pyruvate dehydrogenase and carbohydrate metabolism. Always administer oral or IV thiamine ( 100 – 200 mg 100\text{--}200\text{ mg} 100 – 200 mg daily) before initiating caloric reintroduction to prevent acute Wernicke encephalopathy and lactic acidosis.
Risk-Calibrated Refeeding : Use a specialist protocol that avoids both refeeding syndrome and underfeeding. MEED 2022 (updated 2025) supports adolescent starts of 1400–2000 kcal/day , increasing by at least 200 kcal/day , except at highest risk. Its high-risk pathway starts at 20 kcal/kg/day , increasing by 5 kcal/kg every 2 days with close monitoring. Choose the pathway from clinical risk, recent intake and malnutrition severity; NICE does not prescribe a universal 1200–1400 kcal start.
Electrolyte Monitoring and Replacement : Monitor phosphate, potassium and magnesium frequently during early refeeding; high-risk patients may need 12–24-hourly tests initially. Use age-appropriate ranges and the specialist protocol for preventive supplementation or correction. Oral/enteral phosphate is preferred for mild/moderate asymptomatic deficiency; use monitored IV replacement for severe or symptomatic hypophosphataemia or when enteral treatment is unsuitable. Correct deficiencies alongside nutritional rehabilitation.
Fluid Restriction : Avoid aggressive IV fluid boluses. Starved hearts possess atrophic left ventricular mass; excessive sodium and fluid loading rapidly triggers acute congestive heart failure and pulmonary edema.